| Stem Cell Niche Mimetic |
Human mesenchymal stem cells (hMSC) are multi-potent and can differentiate into various cell lineages of mesenchymal tissues including, bone, cartilage, fat, tendon, muscle, adipocytes, chondrocytes, and osteocytes. hMSCs accordingly have tremendous potential to provide different cell types for use in a variety of medical and research purposes.
Stem cells including hMSC require adhesion to an ECM for survival and growth.
Traditional culture methods for proliferating human stem cells require the use of mouse embryonic fibroblasts (MEFs) as a feeder layer, which could result in cross-contamination of the human stem cell population with animal components. Contamination of stem cells or their differentiated derivatives with animal components increases the likelihood of immune rejection during regenerative therapies.
Kollodis have made effort to address this issue by developing MAPTrix™ based stem cell niche microenvironment.
As evidenced in cord blood-derived mesenchymal stem cell growth and differentiation under low/no serum conditions, our MAPTrix™ technology demonstrated ECM mediated stem cell survival, growth, and differentiation.
Kollodis have developed MAPTrix™ based stem cell medium as serum-free medium for clinical use in collaboration with a company whose hMSC based therapy is currently in Phase II development in the United States.
The combination of MAPTrix® ECM and MAPTrix® GF is expected to address “animal protein-free, chemically and physically defined issue” in stem cell based therapy.
|
| |
| Stem Cell Carrier |
Cell recruitment to targeted site is a major challenge to improve any cell based therapy. Cell carrier with little immunological rejection/inflammation is one of critical factors to the successful stem cell based therapy.
Mussel adhesive protein does induce little or no inflammatory or immune response in vivo as demonstrated in our rat and mouse model.
As efficient approach, we have developed MAPTrix™ based injectable hydrogel for cell encapsulation |
 |
| MAPTrix® ECM was demonstrated to be used for ECM-mediated adipocyte differentiation control of mesenchymal stem cell into adipocyte in rat model. The adipocyte differentiation was determined by Y chromosome analysis as male MSCs were transplanted into female adipocytes.
|
| |
| Cell carrier with little/no immunogenecity
|
Cell recruitment to targeted site is a major challenge to improve stem cell based therapy. For example, cell carrier with little immunological rejection and/or inflammation is one of critical factors to the successful stem cell based therapy.
Our MAPTrix® ECM did not induce an inflammatory response when MAPTrix® ECM was used as a transplantation matrix for mesenchymal stem cell carrier in rat & mouse models
|
 |
Positive Control:
MSC transplantation without carrier |
| |
| Adhesive Compostion
|
Naturally ocurring mussel adhesive protein has a wide range of adhesive strengths (typically 0.5~1.0 MPa) depending upon the type of pretreatment. Curing conditions and/or joint configuration makes direct comparisons of adhesive strength cumbersome for both medical and non-medical (industrial, commodity) applications. A variety of pretreatment methods may result in different DOPA residue content- a key ingredient for strong adhesion in mussel adhesive protein.
Kollodis' recombinant mussel adhesive protein based adhesive compositions provide consistent, reproducible, and reliable adhesive strengths for your particular application. With our added crosslinking agents, the curing rate and adhesive strength can be adjusted to meet your specific requirements and needs.
Kollodis has developed an adhesive composition for cosmetic glue applications, particularly for eyelash adhesives that require an aldehyde-free adhesive (due to regulatory and hemostatic sealant constraints). Our feasibility tests have demonstrated strong adhesive strengths for eyelashes as compared to conventional cyano-based adhesive compositions.
Currently, our adhesive compositions are undergoing preclinical toxicology studies in both Korea and the United States of America. Our current preclinical studies are being conducted in collaboration with a medical device company for use in cartilage repair and hemostatic sealant applications.
|
 |
| No inflammation or necrosis was observed while the wound site was almost completely recovered with reduced scar formation. With this results, we have been focused on developing a composition with a setting time of less than 5 minutes for clinical and cosmetic applications.
|
| |
 |
